Clinigen Group Plc (CLIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
92
About the Report
About the Report
Summary
Clinigen Group Plc (Clinigen Group) is a pharmaceutical and services company that provides access to clinical trials, medicines, unlicensed and commercial supply. The company acquires and licenses essential commercial medicines such as foscavir, cardioxane, ethyol, savene and vibativ. It offers clinical trial services, global access, IDIS managed access, and strategic services. Clinigen Group's clinical trial services comprise demand-driven labelling and distribution, direct-to-site delivery, ancillary supply, investigator-initiated trial services, and technical consultancy services. It serves biotechnology and pharmaceutical companies, and healthcare professionals. The company has its operations in Japan, the US, New Zealand, Australia, Singapore, South Africa, and the UK. Clinigen Group is headquartered in Burton-on-Trent, the UK.
Clinigen Group Plc (CLIN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Clinigen Group Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Clinigen Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Clinigen Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Clinigen Acquires Imukin from Horizon Pharma 15
Clinigen Acquires Proleukin from Novartis 16
Clinigen Acquires Rights to Totect from Biocodex USA 17
Clinigen Group Acquires Ethyol from AstraZeneca 18
Clinigen Acquires Savene, Oncology Support Therapy, From SpePharm 19
Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For USD 33 Million 20
Partnerships 21
Clinigen Enters into Distribution Agreement with Lukare Medical 21
Clinigen and Bristol-Myers Squibb Enter into Agreement 22
Clinigen Enters into Agreement with Shionogi 23
Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 24
Clinigen Enters into Distribution Agreement with Romark Labs 25
Clinigen Group Enters into Distribution Agreement with BioQ Pharma 26
Clinigen Group Partners with Horizon Pharma 27
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 28
Cumberland Pharma Enters into Agreement with Clinigen 29
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 30
Link Healthcare Enters Into Agreement With Sanochemia Pharmazeutika For Secrelux 31
Licensing Agreements 32
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 32
Quantum Pharma Enters into Licensing Agreement with Moorfields Pharma 33
Quantum Pharma Enters into Licensing Agreement with Futura Medical 34
German Pharma Company Enters into Licensing Agreement with Colonis Pharma 35
Clinigen Extends Licensing Agreement with Hospira for Foscavir 36
Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 37
Quantum Pharma Enters into Licensing Agreements 39
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 40
Equity Offering 41
Clinigen Group to Raise USD105.35 Million in Equity Offering of Shares 41
Clinigen Raises USD105.4 Million in Private Placement of Shares 42
Quantum Pharma to Raise USD18.43 Million in Private Placement of shares 44
Quantum Pharma Raises USD167 Million in IPO 45
Clinigen Completes IPO For USD 16 Million 46
Acquisition 48
Clinigen Acquires iQone Healthcare for USD8.8 Million 48
NuPharm Acquires Laboratoire Biodim from Pharma Omnium International 50
Clinigen Acquires Quantum Pharma for USD199 Million 51
Clinigen Group Acquires Link Healthcare for USD78.2 Million 53
Quantum Pharma Acquires NuPharm 54
Clinigen Group Acquires Idis Group for USD338 Million 55
Quantum Pharma Acquires Lamda, Lamda Labs and Lamda Pharma for USD10.4 million 56
Link Healthcare Acquires Equity Pharma Holdings, Pharma And Medical Technology Company 57
Clinigen Group Plc-Key Competitors 58
Clinigen Group Plc-Key Employees 59
Clinigen Group Plc-Locations And Subsidiaries 60
Head Office 60
Other Locations & Subsidiaries 60
Recent Developments 62
Financial Announcements 62
Sep 27, 2018: Clinigen Group: Diversified portfolio drives strong financial results 62
Feb 27, 2018: Clinigen Group: Good H1 Performance With Adjusted EPS Up 13% 75
Sep 28, 2017: Clinigen Group: Full Year Results for the Year Ended 30 June 2017 76
Mar 15, 2017: Clinigen Group: Strong H1 Performance with Adjusted EPS up 31% 77
Jan 25, 2017: Clinigen Group HY trading update: strong H1 performance with gross profit up 34% 84
Corporate Communications 86
Mar 06, 2018: Clinigen strengthens senior management team in clinical trial services and commercial medicines 86
Dec 06, 2017: Clinigen Group:Directorate Change 87
Nov 01, 2017: Clinigen Group: Board changes 88
Other Significant Developments 90
Jul 18, 2017: Clinigen Group: Year End Trading Update 90
Appendix 92
Methodology 92
About GlobalData 92
Contact Us 92
Disclaimer 92
List of Figure
List of Figures
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Clinigen Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
List of Table
List of Tables
Clinigen Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Clinigen Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Clinigen Group Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Clinigen Group Plc, Medical Devices Deals, 2012 to YTD 2018 12
Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Clinigen Acquires Imukin from Horizon Pharma 15
Clinigen Acquires Proleukin from Novartis 16
Clinigen Acquires Rights to Totect from Biocodex USA 17
Clinigen Group Acquires Ethyol from AstraZeneca 18
Clinigen Acquires Savene, Oncology Support Therapy, From SpePharm 19
Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For USD 33 Million 20
Clinigen Enters into Distribution Agreement with Lukare Medical 21
Clinigen and Bristol-Myers Squibb Enter into Agreement 22
Clinigen Enters into Agreement with Shionogi 23
Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 24
Clinigen Enters into Distribution Agreement with Romark Labs 25
Clinigen Group Enters into Distribution Agreement with BioQ Pharma 26
Clinigen Group Partners with Horizon Pharma 27
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 28
Cumberland Pharma Enters into Agreement with Clinigen 29
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 30
Link Healthcare Enters Into Agreement With Sanochemia Pharmazeutika For Secrelux 31
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 32
Quantum Pharma Enters into Licensing Agreement with Moorfields Pharma 33
Quantum Pharma Enters into Licensing Agreement with Futura Medical 34
German Pharma Company Enters into Licensing Agreement with Colonis Pharma 35
Clinigen Extends Licensing Agreement with Hospira for Foscavir 36
Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 37
Quantum Pharma Enters into Licensing Agreements 39
Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 40
Clinigen Group to Raise USD105.35 Million in Equity Offering of Shares 41
Clinigen Raises USD105.4 Million in Private Placement of Shares 42
Quantum Pharma to Raise USD18.43 Million in Private Placement of shares 44
Quantum Pharma Raises USD167 Million in IPO 45
Clinigen Completes IPO For USD 16 Million 46
Clinigen Acquires iQone Healthcare for USD8.8 Million 48
NuPharm Acquires Laboratoire Biodim from Pharma Omnium International 50
Clinigen Acquires Quantum Pharma for USD199 Million 51
Clinigen Group Acquires Link Healthcare for USD78.2 Million 53
Quantum Pharma Acquires NuPharm 54
Clinigen Group Acquires Idis Group for USD338 Million 55
Quantum Pharma Acquires Lamda, Lamda Labs and Lamda Pharma for USD10.4 million 56
Link Healthcare Acquires Equity Pharma Holdings, Pharma And Medical Technology Company 57
Clinigen Group Plc, Key Competitors 58
Clinigen Group Plc, Key Employees 59
Clinigen Group Plc, Subsidiaries 60
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.